+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019

  • ID: 4901398
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 684 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adocia SAS
  • Axxam SpA
  • Dualogics Corp
  • Kamada Ltd
  • Pandion Therapeutics Inc
  • Semma Therapeutics Inc
  • MORE
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 6, 3, 11, 35, 23, 1, 115, 23 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 2, 1, 30 and 4 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adocia SAS
  • Axxam SpA
  • Dualogics Corp
  • Kamada Ltd
  • Pandion Therapeutics Inc
  • Semma Therapeutics Inc
  • MORE
Introduction
Type 1 Diabetes (Juvenile Diabetes) - Overview
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H2 2019
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aerami Therapeutics, H2 2019
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ahead Therapeutics SL, H2 2019

List of Figures
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adocia SAS
  • Aerami Therapeutics
  • Ahead Therapeutics SL
  • Akston Biosciences Corp
  • Algiax Pharmaceuticals GmbH
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Altheia Science SRL
  • ALTuCELL
  • Amarantus Bioscience Holdings Inc
  • Amarna Therapeutics BV
  • AmideBio LLC
  • Anokion SA
  • apceth Biopharma GmbH
  • Aphios Corp
  • Apodemus AB
  • APT Therapeutics Inc
  • Aptamer Sciences Inc
  • Arecor Ltd
  • Ariddad Therapeutics SL
  • Artery Therapeutics Inc
  • AstraZeneca Plc
  • Atlantic Bio Sci LLC
  • Auxulin Pharmaceuticals Inc
  • AVM Biotechnology LLC
  • Avotres Inc
  • Axxam SpA
  • Beta-Cell NV
  • Biocon Ltd
  • BioLineRx Ltd
  • BioLingus AG
  • Bioorg3.14 LLC
  • Biozeus Pharmaceutical SA
  • BirchBioMed Inc
  • Boehringer Ingelheim International GmbH
  • Bol Pharma
  • Boston Therapeutics Inc
  • Bristol-Myers Squibb Co
  • BTB Pharma AB
  • Cancer Prevention Pharmaceuticals Inc
  • CAR-T (Shanghai) Biotechnology Co Ltd
  • Carlina Technologies SAS
  • CellTrans Inc
  • Chongqing Chenan BioPharm Co Ltd
  • Compugen Ltd
  • Cour Pharmaceuticals Development Co Inc
  • CRISPR Therapeutics AG
  • Cyteir Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Denceptor Therapeutics Ltd
  • Dendright Pty Ltd
  • Diabetology (Products) Ltd
  • Diamyd Medical AB
  • Diasome Pharmaceuticals Inc
  • DiaVacs Inc
  • Dompe Farmaceutici SpA
  • Dualogics Corp
  • Eli Lilly and Co
  • Endsulin LLC
  • Ensol Biosciences Inc
  • Enthera Srl
  • EpiVax Inc
  • Evotec SE
  • Fairbanks Pharmaceuticals Inc
  • FasCure Therapeutics LLC
  • Follicum AB
  • Gan & Lee Pharmaceutical Ltd
  • Generex Biotechnology Corp
  • GeNeuro SA
  • Geropharm
  • Gubra ApS
  • Hanmi Pharmaceuticals Co Ltd
  • Housey Pharmaceutical Research Laboratories LLC
  • Iltoo Pharma
  • ImCyse SA
  • ImmunoMolecular Therapeutics LLC
  • ImmusanT Inc
  • Innovimmune Biotherapeutics Inc
  • Intrexon Corp
  • Inversago Pharma Inc
  • Islexa Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • JN Biosciences LLC
  • Johnson & Johnson
  • Jortan Pharmaceuticals Inc
  • Kadimastem Ltd
  • Kamada Ltd
  • Kunming Yinnuo Medical Technology Co. Ltd.
  • L2 Diagnostics LLC
  • Landos Biopharma Inc
  • Larix Bioscience LLC
  • Lexicon Pharmaceuticals Inc
  • MannKind Corp
  • Maruho Co Ltd
  • Medytox Inc
  • Mercia Pharma Inc
  • Merck & Co Inc
  • Metavant Sciences Ltd
  • MidaSol Therapeutics LP
  • Neovacs SA
  • NextCell Pharma AB
  • Novartis AG
  • Novo Nordisk AS
  • OneVax LLC
  • Op-T-Mune Inc
  • Oramed Pharmaceuticals Inc
  • Orgenesis Inc
  • Orion BioScience Inc
  • OSE Immunotherapeutics
  • Pancryos
  • Pandion Therapeutics Inc
  • Paras Biopharmaceuticals Finland Oy
  • Parvus Therapeutics Inc
  • Pfizer Inc
  • PharmaCyte Biotech Inc
  • PharmaIN Corp
  • PolTREG Sp z o o
  • Polus Inc
  • Prometheon Pharma LLC
  • Protomer Technologies Inc
  • Provention Bio Inc
  • Purzer Pharmaceutical Co Ltd
  • Radikal Therapeutics Inc
  • RedHill Biopharma Ltd
  • REGiMMUNE Corp
  • Reliance Life Sciences Pvt Ltd
  • Remd Biotherapeutics Inc
  • reMYND NV
  • Renova Therapeutics Inc
  • Rezolute Inc
  • Rubius Therapeutics Inc
  • SAB Biotherapeutics Inc
  • Sahane Biotech Inc
  • Sanofi
  • Semma Therapeutics Inc
  • Sensulin LLC
  • Seraxis Inc
  • Serpin Pharma LLC
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Sotio AS
  • SQZ Biotechnologies Co
  • Suntec Medical (Taiwan) Inc
  • SymbioCellTech LLC
  • Tetragenetics Inc
  • Thermalin Diabetes LLC
  • Toleranzia AB
  • Tolerion Inc
  • Tolerx, Inc. (Inactive)
  • Topas Therapeutics GmbH
  • Transgene Biotek Ltd
  • Unicyte AG
  • Valin Technologies Ltd
  • Ventria Bioscience
  • Veralox Therapeutics Inc
  • ViaCyte Inc
  • ViCapsys Inc
  • Virtici LLC
  • vTv Therapeutics Inc
  • XERIS Pharmaceuticals Inc
  • XL-protein GmbH
  • Yichang Hec Changjiang Pharmaceutical Co Ltd
  • Youngene Therapeutics Co Ltd
  • Zealand Pharma AS
  • Zhejiang Hisun Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll